Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide

被引：1
作者：
Dib, Elie G. [1 ]
Antonarakis, Emmanuel S. [3 ]
Wasco, Matthew J. [2 ]
Powell, Steven F. [4 ]
机构：
[1] Trinity Hlth IHA Hematol Oncol Consultants, Ann Arbor, MI USA
[2] Trinity Hlth IHA Pathol, Ann Arbor, MI USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Sanford Canc Ctr, Sioux Falls, SD USA
来源：
CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 02期
关键词：
CDK12; Checkpoint inhibitor; Homologous recombination; Mismatch-repair deficiency; PDL-1; UNITED-STATES; RACE;
D O I：
10.1016/j.clgc.2018.11.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E365 / E368
页数：4
相关论文
共 16 条
  • [1] [Anonymous], J CLIN ONCOL S
  • [2] [Anonymous], 2018, CANC FACTS FIG
  • [3] Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
    Antonarakis, Emmanuel S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11) : 1087 - 1089
  • [4] PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
    Bishop, Jennifer L.
    Sio, Alexander
    Angeles, Arkhjamil
    Roberts, Morgan E.
    Azad, Arun A.
    Chi, Kim N.
    Zoubeidi, Amina
    [J]. ONCOTARGET, 2015, 6 (01) : 234 - 242
  • [5] Boudadi Karim, 2018, Oncotarget, V9, P28561, DOI 10.18632/oncotarget.25564
  • [6] Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
    Graff, Julie N.
    Alumkal, Joshi J.
    Drake, Charles G.
    Thomas, George V.
    Redmond, William L.
    Farhad, Mohammad
    Cetnar, Jeremy P.
    Ey, Frederick S.
    Bergan, Raymond C.
    Slottke, Rachel
    Beer, Tomasz M.
    [J]. ONCOTARGET, 2016, 7 (33) : 52810 - 52817
  • [7] Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
    Haffner, Michael C.
    Guner, Gunes
    Taheri, Diana
    Netto, George J.
    Palsgrove, Doreen N.
    Zheng, Qizhi
    Guedes, Liana Benevides
    Kim, Kunhwa
    Tsai, Harrison
    Esopi, David M.
    Lotan, Tamara L.
    Sharma, Rajni
    Meeker, Alan K.
    Chinnaiyan, Arul M.
    Nelson, William G.
    Yegnasubramania, Srinivasan
    Luo, Jun
    Mehra, Rohit
    Antonarakis, Emmanuel S.
    Drake, Charles G.
    de Marzo, Angelo M.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (06) : 1478 - 1485
  • [8] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
  • [9] Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014
    Li, Jun
    Siegel, David A.
    King, Jessica B.
    [J]. ANNALS OF EPIDEMIOLOGY, 2018, 28 (05) : 328 - 330
  • [10] Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
    Li, Likun
    Karanika, Styliani
    Yang, Guang
    Wang, Jiangxiang
    Park, Sanghee
    Broom, Bradley M.
    Manyam, Ganiraju C.
    Wu, Wenhui
    Luo, Yong
    Basourakos, Spyridon
    Song, Jian H.
    Gallick, Gary E.
    Karantanos, Theodoros
    Korentzelos, Dimitrios
    Azad, Abul Kalam
    Kim, Jeri
    Corn, Paul G.
    Aparicio, Ana M.
    Logothetis, Christopher J.
    Troncoso, Particia
    Heffernan, Timothy
    Toniatti, Carlo
    Lee, Hyun-Sung
    Lee, Ju-Seog
    Zuo, Xuemei
    Chang, Wenjun
    Yin, Jianhua
    Thompson, Timothy C.
    [J]. SCIENCE SIGNALING, 2017, 10 (480)
12